Toward a More Precise Future for Oncology

Murciano-Goroff, Yonina R.; Taylor, Barry S.; Hyman, David M.; Schram, Alison M.

doi:10.1016/j.ccell.2020.03.014

Cited by 48Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsChromatin Remodeling and Cancer

Toward a More Precise Future for Oncology

Open access

Murciano-Goroff, Yonina R., Taylor, Barry S., Hyman, David M., Schram, Alison M.·2020·Cancer Cell

DOI 10.1016/j.ccell.2020.03.014PMC PMC7499397

Open this paper in CoChat — free account Open PDF

Abstract

Prospective molecular characterization of cancer has enabled physicians to define the genomic changes of each patient's tumor in real time and select personalized therapies based on these detailed portraits. Despite the promise of such an approach, previously unrecognized biological and therapeutic complexity is emerging. Here, we synthesize lessons learned and discuss the steps required to extend the benefits of genome-driven oncology, including proposing strategies for improved drug design, more nuanced patient selection, and optimized use of available therapies. Finally, we suggest ways that next-generation genome-driven clinical trials can evolve to accelerate our understanding of cancer biology and improve patient outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2020.03.014

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Functional precision medicine is based on testing drug responses on patient tumors to identify effective regimens and does not require prior knowledge of a tumor molecular profile.
“FPM is based on testing drug responses on patient tumors to identify effective regimens and does not require any knowledge of a tumor molecular profile or characteristics a priori.”
From Organoids (2022) · cites this paper as [166]
The Introduction and Improved Patient Selection sections discuss genomically guided treatment, not functional precision medicine. Searches for functional precision medicine, drug-response testing on patient tumors, and treatment selection without a prior molecular profile found no passage addressing the claim in our copy. (LLM, conf=0.76)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works
Self-citation
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379 · see citing works
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914 · see citing works
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · see citing works
Self-citation
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P. L., Mackiewicz, A. A., Stroyakovskiy, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,698 · see citing works
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527 · see citing works
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · see citing works
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198 · see citing works
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185 · see citing works
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006 · see citing works
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · see citing works
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964 · see citing works
Self-citation
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,916 · see citing works
Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790 · see citing works
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., PAQUETTE, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,608 · see citing works
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,540 · see citing works
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandalà, M., Chiarion‐Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,510 · see citing works
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,506 · see citing works
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495 · see citing works
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · see citing works
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., García-Donás, J., Huddart, R. A., Burgess, E. F., Fleming, M. T., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,370 · see citing works
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
DeMatteo, R. P., Ballman, K. V., Antonescu, C. R., Maki, R. G., Pisters, P. W. T., Demetri, G. D., Blackstein, M. E., Blanke, C. D., von Mehren, M., Brennan, M. F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60500-6 · Cited by 1,368 · see citing works
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3860 · Cited by 1,365 · see citing works
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
Planchard, D., Smit, E. F., Groen, H. J. M., Mazières, J., Besse, B., Helland, Å., Giannone, V., D'amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360 · see citing works
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
O’Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,268 · see citing works
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217 · see citing works
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192 · see citing works
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · see citing works
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo‐Jack, I., Gadgeel, S. M., Schultz, K. R., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,158 · see citing works
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Virós, A., Milagre, C. S., Trunzer, K., Bollag, G. E., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038 · see citing works
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A. M., Mandalà, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,034 · see citing works
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Perez, E. A., Romond, E. H., Suman, V. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5730 · Cited by 981 · see citing works
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980 · see citing works
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968 · see citing works
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960 · see citing works
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
Planchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30146-2 · Cited by 888 · see citing works
The long tail of oncogenic drivers in prostate cancer
PCF/SU2C International Prostate Cancer Dream Team, Armenia, J., Wankowicz, S. A. M., Liu, D., Gao, J., Kundra, R., Reznik, E., Chatila, W. K., Chakravarty, D., Han, G. C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0078-z · Cited by 873 · see citing works
Self-citation
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A. C., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 823 · see citing works
Dragging ras back in the ring
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · see citing works
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780 · see citing works
Self-citation
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J. A., Dienstmann, R., Serra, V., & Tabernero, J. M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 770 · see citing works
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · see citing works
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · see citing works
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
McGranahan, N., Favero, F., de Bruin, E. C., Birkbak, N. J., Szallasi, Z., & Swanton, C. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1408 · Cited by 685 · see citing works
Protein-tyrosine phosphatases and cancer
Östman, A., Hellberg, C. B., & Böhmer, F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1837 · Cited by 657 · see citing works
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638 · see citing works
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
O’Hare, T., Eide, C. A., & Deininger, M. W. (2007) · Blood · doi:10.1182/blood-2007-03-066936 · Cited by 634 · see citing works
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Oxnard, G. R., Arcila, M. E., Sima, C. S., Riely, G. J., Chmielecki, J., Kris, M. G., Pao, W., Ladanyi, M., & Miller, V. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2692 · Cited by 627 · see citing works
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Wylie, A. A., Schoepfer, J. G., Jahnke, W., Cowan‐Jacob, S. W., Loo, A. T., Furet, P., Marzinzik, A. L., Pellé, X., Donovan, J., Zhu, W. S., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 622 · see citing works
Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 595 · see citing works
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A. M., Mandalà, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30497-2 · Cited by 589 · see citing works
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
Ou, S. I., Ahn, J. S., Petris, L. D., Govindan, R., Yang, J. C., Hughes, B. G. M., Léna, H., Moro‐Sibilot, D., Bearz, A., Viteri, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 584 · see citing works
Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study
Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E., Agate, L., Vivaldi, A., Faviana, P., Basolo, F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1714 · Cited by 531 · see citing works
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Baselga, J. M., Im, S., Iwata, H., Cortés, J., Laurentiis, M. D., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M. J., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 529 · see citing works
RET revisited: expanding the oncogenic portfolio
Mulligan, L. M. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3680 · Cited by 515 · see citing works
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507 · see citing works
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Doi, T., Shitara, K., Naito, Y., Shimomura, A., Fujiwara, Y., Yonemori, K., Shimizu, C., Shimoi, T., Kuboki, Y., Matsubara, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30604-6 · Cited by 507 · see citing works
Implementing Genome-Driven Oncology
Hyman, D. M., Taylor, B. S., & Baselga, J. M. (2017) · Cell · doi:10.1016/j.cell.2016.12.015 · Cited by 505 · see citing works
Self-citation
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
Drilon, A. E. D. C., Rekhtman, N., Arcila, M. E., Wang, L., Ni, A., Albano, M., van Voorthuysen, M., Somwar, R., Smith, R. S., Montecalvo, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30562-9 · Cited by 489 · see citing works
Development of targeted protein degradation therapeutics
Chamberlain, P. P., & Hamann, L. G. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0362-y · Cited by 489 · see citing works
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Réa, D., DeAngelo, D. J., Breccia, M., Goh, Y. T., Talpaz, M., Hochhaus, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902328 · Cited by 473 · see citing works
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00614-2 · Cited by 471 · see citing works
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 470 · see citing works
Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468 · see citing works
Selective RET kinase inhibition for patients with RET-altered cancers
Subbiah, V., Velcheti, V., Tuch, B. B., Ebata, K. T., Busaidy, N. L., Cabanillas, M. E., Wirth, L. J., Stock, S. J., Smith, S. G., Lauriault, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy137 · Cited by 433 · see citing works
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Shimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431 · see citing works
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Nogová, L., Sequist, L. V. D., Pérez-García, J. M., André, F., Delord, J., Hidalgo, M. M., Schellens, J. H. M., Cassier, P. A., Camidge, D. R., Schüler, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2048 · Cited by 430 · see citing works
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
O’Leary, B., Hrebien, S., Morden, J. P., Beaney, M., Fribbens, C. V., Huang, X., Liu, Y., Bartlett, C. H., Koehler, M. T., Cristofanilli, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03215-x · Cited by 418 · see citing works
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
Nichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0169-1 · Cited by 415 · see citing works
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
García-Murillas, I., Chopra, N., Comino‐Méndez, I., Beaney, M., Tovey, H., Cutts, R. J., Swift, C., Kriplani, D., Afentakis, M., Hrebien, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1838 · Cited by 414 · see citing works
Adaptive platform trials: definition, design, conduct and reporting considerations
Coalition, T. A. P. T., Angus, D. C., Alexander, B. M., Berry, S., Buxton, M., Lewis, R. J., Paoloni, M., Webb, S. A. R., Arnold, S. E., Barker, A., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0034-3 · Cited by 414 · see citing works
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Drilon, A. E. D. C., Hu, Z. I., Lai, G. G. Y., & Tan, D. S. W. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.175 · Cited by 409 · see citing works
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Subbiah, V., Gainor, J. F., Rahal, R., Brubaker, J. D., Kim, J. L., Maynard, M., Hu, W., Cao, Q., Sheets, M. P., Wilson, D. P., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0338 · Cited by 408 · see citing works
Tumour lineage shapes BRCA-mediated phenotypes
Jonsson, P., Bandlamudi, C., Cheng, M. L., Srinivasan, P., Chavan, S. S., Friedman, N. D., Rosen, E. Y., Richards, A. L., Bouvier, N., Selçuklu, S. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1382-1 · Cited by 404 · see citing works
Self-citation
Accelerating Discovery of Functional Mutant Alleles in Cancer
Chang, M. T., Shrestha-Bhattarai, T., Schram, A. M., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., Chakravarty, D., Phillips, S. M., Kandoth, C., Penson, A. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0321 · Cited by 402 · see citing works
Self-citation
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394 · see citing works
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 380 · see citing works
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Chan, R. J., & Feng, G. (2006) · Blood · doi:10.1182/blood-2006-07-028829 · Cited by 378 · see citing works
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370 · see citing works
Targeting RET in Patients With RET -Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Gautschi, O. P., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D. H., Camidge, D. R., Narayanan, V., Doebele, R. C., Besse, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.9352 · Cited by 364 · see citing works
Saturation editing of genomic regions by multiplex homology-directed repair
Findlay, G. M., Boyle, E. A., Hause, R. J., Klein, J. C., & Shendure, J. (2014) · Nature · doi:10.1038/nature13695 · Cited by 362 · see citing works
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Tamura, K., Tsurutani, J., Takahashi, S., Iwata, H., Krop, I. E., Redfern, C. H., Sagara, Y., Doi, T., Park, H., Murthy, R. K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30097-x · Cited by 354 · see citing works
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK -Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Crinò, L., Ahn, M., de Marinis, F., Groen, H. J. M., Wakelee, H. A., Hida, T., Mok, T. S. K., Spigel, D. R., Felip, E., Nishio, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5936 · Cited by 350 · see citing works
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Zhang, S., Anjum, R., Squillace, R. M., Nadworny, S., Zhou, T., Keats, J. A., Ning, Y., Wardwell, S., Miller, D., Song, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0569 · Cited by 336 · see citing works
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis
Johung, K. L., Yeh, N., Desai, N. B., Williams, T. M., Lautenschlaeger, T., Arvold, N. D., Ning, M. S., Attia, A. A., Lovly, C. M., Goldberg, S. B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0138 · Cited by 333 · see citing works
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Schram, A. M., Chang, M. T., Jonsson, P., & Drilon, A. E. D. C. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.127 · Cited by 328 · see citing works
Self-citation
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324 · see citing works
KRAS as a Therapeutic Target
McCormick, F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2662 · Cited by 320 · see citing works
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0023-9 · Cited by 320 · cited 1× · see citing works
“…exchange, allowing RAS to cycle between its inactive GDP-bound and its activated GTP-bound states (Chan and Feng, 2007; Grossmann et al., 2010; Lu et al., 2019; Mai and Lito, 2018; Mainardi et al., 2018; Matozaki et al., 2009; Nichols et al., 2018; Ostman et al., 2006; Ruess et al., 2018).”
Background
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
Gadgeel, S. M., Peters, S., Mok, T. S. K., Shaw, A. T., Kim, D. W., Ou, S. I., Pérol, M., Wrona, A., Novello, S., Rosell, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy405 · Cited by 319 · see citing works
AKT Inhibition in Solid Tumors With AKT1 Mutations
Hyman, D. M., Smyth, L. M., Donoghue, M. T. A., Westin, S. N., Bedard, P. L., Dean, E. J., Bando, H., El-Khoueiry, A. B., Fidalgo, J. A. P., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0143 · Cited by 309 · see citing works
Self-citation
Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
Coats, S. R., Williams, M. B., Kebble, B., Dixit, R., Tseng, L., Yao, N., Tice, D. A., & Soria, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0272 · Cited by 290 · see citing works
Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features
Buisson, R., Langenbucher, A., Bowen, D., Kwan, E. E., Benes, C. H., Zou, L., & Lawrence, M. S. (2019) · Science · doi:10.1126/science.aaw2872 · Cited by 287 · see citing works
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Kato, S., Subbiah, V., Marchlik, E., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1679 · Cited by 285 · see citing works
The Tyrosine Phosphatase Shp2 in Development and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06002-1 · Cited by 277 · see citing works
Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
Milojković, D., & Apperley, J. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1068 · Cited by 265 · see citing works
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
Ortiz‐Cuaran, S., Scheffler, M., Plenker, D., Dahmen, L., Scheel, A. H., Fernandez‐Cuesta, L., Meder, L., Lovly, C. M., ten Persigehl, T., Merkelbach‐Bruse, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1915 · Cited by 264 · see citing works
Protein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation
Matozaki, T., Murata, Y., Saito, Y., Okazawa, H., & Ohnishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01257.x · Cited by 240 · see citing works
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Shitara, K., Iwata, H., Takahashi, S., Tamura, K., Park, H., Modi, S., Tsurutani, J., Kadowaki, S., Yamaguchi, K., Iwasa, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30088-9 · Cited by 232 · see citing works
VEGF Inhibition, Hypertension, and Renal Toxicity
Hayman, S. R., Leung, N., Grande, J. P., & Garovic, V. D. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0242-z · Cited by 231 · see citing works
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., Patton, D. R., Hamilton, S. R., Williams, P. M., Mitchell, E. P., Iafrate, A. J., Sklar, J., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz245 · Cited by 222 · see citing works
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Cocco, E., Schram, A. M., Kulick, A. R., Misale, S., Won, H. H., Yaeger, R. D., Razavi, P., Ptashkin, R. N., Hechtman, J. F., Toska, E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0542-z · Cited by 220 · see citing works
Self-citation
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib
Naidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211 · see citing works
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin, H., Choi, Y., Yun, J. W., Kim, N. K. D., Kim, S., Jeon, H. J., Nam, J., Lee, C., Ryu, D., Kim, S. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01470-y · Cited by 202 · see citing works
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
Blandino, G., & Agostino, S. D. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0705-7 · Cited by 198 · see citing works
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
Zhang, I., Zaorsky, N. G., Palmer, J. D., Mehra, R., & Lu, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00013-3 · Cited by 192 · see citing works
Tumor Evolution as a Therapeutic Target
Amirouchene-Angelozzi, N., Swanton, C., & Bardelli, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0343 · Cited by 191 · see citing works
Therapeutic targeting of oncogenic tyrosine phosphatases
Frankson, R., Yu, Z.-H., Bai, Y., Li, Q., Zhang, R.-Y., & Zhang, Z.-Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1510 · Cited by 189 · see citing works
Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
Moura, M. M., Cavaco, B. M., Pinto, A. E., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605056 · Cited by 177 · see citing works
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
Fakih, M., O'Neil, B., Price, T. J., Falchook, G. S., Desai, J., Kuo, J., Govindan, R., Rasmussen, E., Morrow, P. K. H., Ngang, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3003 · Cited by 172 · see citing works
The power of multiplexed functional analysis of genetic variants
Gasperini, M., Starita, L., & Shendure, J. (2016) · Nature Protocols · doi:10.1038/nprot.2016.135 · Cited by 160 · see citing works
Crizotinib resistance: implications for therapeutic strategies
Dagogo‐Jack, I., & Shaw, A. T. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw305 · Cited by 159 · see citing works
FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer
Wedam, S. B., Fashoyin‐Aje, L. A., Bloomquist, E. W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2580 · Cited by 159 · see citing works
FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone
Wöhrle, S., Bonny, O., Beluch, N., Gaulis, S., Stamm, C., Scheibler, M., Müller, M. M., Kinzel, B., Thuery, A., Brueggen, J., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.478 · Cited by 152 · see citing works
Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
Azad, N. S., Aragon‐Ching, J. B., Dahut, W. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1141 · Cited by 145 · see citing works
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
DuBois, S. G., Laetsch, T. W., Federman, N. C., et al. (2018) · Cancer · doi:10.1002/cncr.31701 · Cited by 138 · see citing works
Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer
Khozin, S., Miksad, R. A., Adami, J., Boyd, M. E., Brown, N. R., Gossai, A., Kaganman, I., Kuk, D., Rockland, J. M., Pazdur, R., et al. (2019) · Cancer · doi:10.1002/cncr.32383 · Cited by 138 · see citing works
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Liu, D., Offin, M. D., Harnicar, S. J., Li, B. T., & Drilon, A. E. D. C. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s147381 · Cited by 127 · see citing works
Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4.
Gattineni, J., Alphonse, P., Zhang, Q., Mathews, N., Bates, C., & Baum, M. (2014) · AJP - Renal Physiology · doi:10.1152/ajprenal.00232.2013 · Cited by 126 · see citing works
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
Lai, G. G. Y., Lim, T. H., Lim, J., Liew, P. J. R., Kwang, X. L., Nahar, R., Aung, Z. W., Takano, A., Lee, Y. Y., Lau, D. P. X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00177 · Cited by 118 · see citing works
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Drilon, A. E. D. C., Fu, S., Patel, M. R., Fakih, M., Wang, D., Olszanski, A. J., Morgensztern, D., Liu, S. V., Cho, B. C., Bazhenova, L. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0839 · Cited by 112 · see citing works
Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas
Dvořáková, Š., Václavíková, E., Sýkorová, V., et al. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.12.016 · Cited by 111 · see citing works
Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).
Gainor, J. F., Lee, K. H., Curigliano, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9008 · Cited by 110 · see citing works
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2 -Mutant Metastatic Breast Cancer
Smyth, L. M., Piha-Paul, S. A., Won, H. H., Schram, A. M., Saura, C., Loi, S., Lu, J. M., Shapiro, G. I., Juric, D., Mayer, I. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0966 · Cited by 108 · see citing works
Self-citation
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Deininger, M. W., Hodgson, J., Shah, N. P., Cortes, J. E., Kim, D., Nicolini, F. E., Talpaz, M., Baccarani, M., Müller, M. C., Li, J., et al. (2015) · Blood · doi:10.1182/blood-2015-08-660977 · Cited by 105 · see citing works
Treatment‐emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)
Wirth, L. J., Tahara, M., Robinson, B., et al. (2018) · Cancer · doi:10.1002/cncr.31344 · Cited by 104 · see citing works
A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
Drilon, A. E. D. C., Subbiah, V., Oxnard, G. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.102 · Cited by 104 · see citing works
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer
Bielski, C. M., Donoghue, M. T. A., Gadiya, M. M., Hanrahan, A. J., Won, H. H., Chang, M. T., Jonsson, P., Penson, A. V., Gorelick, A. N., Harris, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.003 · Cited by 103 · see citing works
Self-citation
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Lu, H., Liu, C., Velazquez, R., Wang, H., Dunkl, L. M., Kazic-Legueux, M., Haberkorn, A., Billy, E., Manchado, E., Brachmann, S. M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0852 · Cited by 90 · see citing works
Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers
Offin, M. D., Feldman, D., Ni, A., Myers, M. L., Lai, W. V., Pentsova, E. I., Boire, A. A., Daras, M., Jordan, E., Solit, D. B., et al. (2019) · Cancer · doi:10.1002/cncr.32461 · Cited by 89 · see citing works
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
Mologni, L., Redaelli, S., Morandi, A., et al. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.06.025 · Cited by 88 · see citing works
Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology
Tao, J. J., Schram, A. M., & Hyman, D. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062016-050343 · Cited by 80 · see citing works
Self-citation
The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine
Dickson, D. J., Johnson, J. E., Bergan, R. C., et al. (2020) · Cell · doi:10.1016/j.cell.2019.12.009 · Cited by 77 · see citing works
Novel Precision Medicine Trial Designs
West, H. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5299 · Cited by 71 · see citing works
Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
Wu, A.-L., Feng, B., Chen, M. Z., Kolumam, G. A., Zavala‐Solorio, J., Wyatt, S. K., Gandham, V. D., Carano, R. A. D., & Sonoda, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057322 · Cited by 67 · see citing works
Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors
Sehgal, K., Patell, R. D., Rangachari, D., et al. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.08.11 · Cited by 55 · see citing works
Imatinib Changed Everything
Longo, D. L. (2017) · New England Journal of Medicine · doi:10.1056/nejme1700833 · Cited by 53 · see citing works
How I treat ALK-positive non-small cell lung cancer
McCusker, M. G., Russo, A., Scilla, K. A., Mehra, R., & Rolfo, C. D. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000524 · Cited by 49 · see citing works
CancerLinQ: Origins, Implementation, and Future Directions
Rubinstein, S. M., & Warner, J. L. (2018) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00060 · Cited by 46 · see citing works
Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma
Moser, J. C., Wei, G., Colonna, S. V., Grossmann, K. F., Patel, S. B., & Hyngstrom, J. R. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1712473 · Cited by 45 · see citing works
Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
Guo, R., Schreyer, M., Chang, J. C., Rothenberg, S. M., Henry, D., Cotzia, P., Kris, M. G., Rekhtman, N., Young, R. J., Hyman, D. M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00021 · Cited by 44 · see citing works
Self-citation
Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
Ackermann, C. J., Stock, G. T., Tay, R. Y., Dawod, M. A. I., Gomes, F., & Califano, R. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s171665 · Cited by 40 · see citing works
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Han, J., Lee, K. H., Kim, S., Min, Y. J., Cho, E., Lee, Y., Lee, S.-H., Kim, H. Y., Lee, G. K., Nam, B., et al. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.058 · Cited by 39 · see citing works
Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.
Taylor, M. H., Gainor, J. F., Hu, M. I.-N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.6018 · Cited by 39 · see citing works
Registrational results of LOXO-292 in patients with RET-altered thyroid cancers
Wirth, L. J., Sherman, E. J., Drilon, A. E. D. C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.093 · Cited by 27 · see citing works
The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers
Brandhuber, B. J., Haas, J., Tuch, B. B., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)33028-3 · Cited by 24 · see citing works
A treatment strategy for KRAS-driven tumors
Mai, T. T., & Lito, P. (2018) · Nature Medicine · doi:10.1038/s41591-018-0111-x · Cited by 24 · see citing works
Systematic pan-cancer analysis of somatic allele frequency
Spurr, L. F., Li, M., Alomran, N., Zhang, Q., Restrepo, P., Movassagh, M. J., Trenkov, C., Tunnessen, N., Apanasovich, T. V., Crandall, K. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25462-0 · Cited by 23 · see citing works
Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Yu, H. A., Ahn, M., Kim, S., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct032 · Cited by 21 · see citing works
Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer
Parikh, R. B., Adamson, B. J. S., Khozin, S., et al. (2019) · JAMA · doi:10.1001/jama.2019.10650 · Cited by 21 · see citing works
Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Sequist, L. V. D., Lee, J. S., Han, J., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct033 · Cited by 18 · see citing works
Quantifying the Benefits of Genome-Driven Oncology
Schram, A. M., & Hyman, D. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0380 · Cited by 14 · see citing works
Self-citation
Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer
Zweig, J. R., & Neal, J. W. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8554 · Cited by 8 · see citing works
P2.13-32 TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2
Chouitar, J., Vincent, S., Brake, R., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.1427 · Cited by 8 · see citing works
Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients
Koyama, T., Rhrissorrakrai, K., & Parida, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5313-1 · Cited by 8 · see citing works
Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors
Schram, A. M., Voss, M. H., & Hyman, D. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5061 · Cited by 7 · see citing works
Self-citation
Meet the Acta Oncologica editorial board
Nilbert, M. C. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1698766 · Cited by 5 · see citing works

Flagged first, then by citations

Research works printed but not linked: 1

[64]Jänne PA, P. K., Ou I, Rybkin I, Johnson M (2019). A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRAS G12C inhibitor, in advanced solid tumors. In AACR-NCI-EORTC International Conference on Molecular Targets (Boston, MA).

Sorted by citations

Organoids
Zhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L. S., Balachander, G. M., Chen, Z., Soragni, A., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00174-y · Cited by 1,001 · see citing works

Authors: Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Schram, Alison M.
ORCID: Murciano-Goroff, Yonina R.
Taylor, Barry S.
Hyman, David M.
Schram, Alison M.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2020-04
Volume: 37
Issue: 4
Pages: 431-442
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccell.2020.03.014
PMC: PMC7499397
OpenAlex: W3015895535
Cited by: 48
References: 160
Citations by year: 2026: 7 · 2025: 7 · 2024: 7 · 2023: 3 · 2022: 11 · 2021: 8 · 2020: 5
FWCI: 2.31
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 377 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: AstraZeneca (CTSA UL1TR00457)
Illumina
National Cancer Institute (P30 CA008748)
Bayer Corporation
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: precision oncology, personalized treatment, drug design, patient selection, cancer genomics
MeSH terms: Drug Development, Antineoplastic Agents, Humans, Neoplasms, Biomarkers, Tumor, Patient Selection, Genomics, Precision Medicine, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Toward a More Precise Future for Oncology

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks